Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

PHASE3TerminatedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2011

Conditions
Proctitis, Ulcerative
Interventions
DRUG

MAX-002

MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.

DRUG

Placebo

Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.

DRUG

Canasa®

Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.

Trial Locations (40)

10075

Research Associates of New York (RANY), New York

11230

Synergy First Medical, Brooklyn

30263

Digestive Research Associates, Newnan

32789

Shafran Gastroenterology Center, Winter Park

33021

Center for Gastrointestinal Disorders, Hollywood

33426

Clinical Research of South Florida, Boynton Beach

34102

Gastroenterology Group of Naples, Naples

35209

Birmingham Gastroenterology Associates P.C., Birmingham

36305

Digestive Health Specialists of the Southeast, Dothan

37203

The First Clinic, Nashville

38138

Memphis Gastroenterology Group, Germantown

39202

Gastrointestinal Associates, Jackson

44195

Cleveland Clinic, Cleveland

45219

Consultants for Clinical Research, Cincinnati

47714

Advanced Pain Care Clinic, Evansville

53215

Wisconsin Center for Advanced Research, Milwaukee

65265

Center for Digestive & Liver Diseases Inc., Mexico

78041

South Texas Research Alliance, Laredo

80229

Rocky Mountain Gastroenterology Associates, Thornton

85710

Desert Sun Gastroenterology, Tucson

06790

Litchfield County Gastroenterology and Associates, Torrington

08053

South Jersey Gastroenterology, Marlton

V2S 3N5

Gastroenterology & Hepatology Clinic, Abbotsford

V5Z 1N9

Diamond Health Care Centre, Vancouver

N1H 3R3

Surrey GI Clinic Research, Guelph

L8N 4A6

St-Joseph's Healthcare Hamilton, Hamilton

L4B 3P8

DHC Research, Richmond Hill

L4L 4Y7

Toronto Digestive Disease Associates Inc. (TDDA), Vaughan

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

G2B 5S1

Alpha Recherche Clinique, Québec

15-351

GASTROMED s.c., Bialystok

42-200

Wojewódzki Szpital Specjalistyczny Oddz. Gastroenterologii, Częstochowa

90-153

SPZOZ Uniwersytecki Szpital Kliniczny, Lodz

90-549

SPZOZ Uniwersytecki Szpital Kliniczny, Lodz

20-718

Wojewodzki Szpital Specjalistyczny, Lublin

20-954

SP Szpital Kliniczny, Lublin

05-800

Szpital Kolejowy, Pruszków

35-068

MEDICOR - Centrum Medyczne, Rzeszów

81-756

Endoskopia SP. Z o.o., Sopot

02-511

Gabinet Lekarski LECHMED, Warsaw

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY